- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02151552
Assessing NOS Uptake With PET Imaging in Lung Inflammation
Assessing [18F](+/-)NOS Uptake With PET Imaging in Endotoxin-induced Lung Inflammation
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
The investigators plan to use three radioactive tracers to produce the PET images for measuring lung inflammation: [18F](+/-)NOS (the F stands for fluorine and NOS stands for Nitric Oxide Synthase, which targets iNOS), O-15 carbon monoxide ([15O]CO), and O-15 water ([15O]H2O). The NOS tracer gives information specifically about lung inflammation, while the carbon monoxide and water tracers give information about whether the lung inflammation causes more blood or water to be retained in the area of lung inflammation.
In order to show that [18F](+/-)NOS-PET is related to the amount of inflammation, the investigators first need to create a state of controlled lung inflammation that can be measured and quantified. "Controlled lung inflammation" means a reaction in the lungs that is similar to that which occurs during lung infection (increased respiratory secretions and cough). It is "controlled" because the investigators will not be using anything alive or contagious (it does not spread from one part of the body to another, and cannot spread to another person), and a small area in only one lung will be affected. In order to created this state of controlled lung inflammation, the investigators plan to place a small amount of a purified bacterial substance called endotoxin into a single small section of the lung using a bronchoscope (a long, flexible narrow tube that is passed through the mouth into the airways of the lung). This use of endotoxin is considered investigational, and the investigators have received permission from the FDA to use endotoxin in this research study.
Study Type
Enrollment (Actual)
Phase
- Early Phase 1
Contacts and Locations
Study Locations
-
-
Missouri
-
Saint Louis, Missouri, United States, 63110
- Washington University School of Medicine / Barnes-Jewish Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Healthy man or woman, any race or ethnicity, age 19-44 years old
- Screening FEV1 and FVC greater than or equal to 90% of predicted
- Screening oxygen saturation by pulse oximetry greater than or equal to 97% on room air
- Capable of lying still and supine with arms raised above the head within PET/CT scanner for 2-2.5 hours
- Capable of following instructions for breathing protocol during CT portion of PET/CT scans
- Able and willing to give informed consent
- Body Mass Index (BMI) < 35
Exclusion Criteria:
- Pregnancy (confirmed by qualitative serum hCG pregnancy test)
- Lactation
- History of cardiopulmonary disease
- Currently taking any prescription medications
- History of tobacco use or illicit drug use within the past year
- Presence of implanted electronic medical device
- Enrollment in another research study of an investigational drug
- Known allergy to both trimethoprim/sulfamethoxazole and amoxicillin, Penicillin, Lidocaine, Demerol, Versed, and/or Fentanyl
- Inability to lie flat for 2-2.5 hours for PET/CT scans or follow breathing protocol instructions for the CT portion of the PET/CT
- Prior research-related radiation exposure within the past year such that participation in this study would result in exposures that exceed the limits as defined by the FDA RDRC regulations (21 CFR 361.1)
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Basic Science
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Endotoxin and [18F](+/-)NOS
All volunteers in this study will receive endotoxin in a single segment of the lung to induce mild, self-limited inflammation.
They will also be imaged before and after endotoxin instillation with the novel PET tracer [18F](+/-)NOS.
|
The endotoxin will be reconstituted with sterile water to a final concentration of 2,000 endotoxin units/ml.
The dose of 4 ng/kg will be prepared to a final volume of 2 ml and will be administered using a 5F balloon-tipped monitoring catheter inserted via a fiberoptic bronchoscope into the lateral segment of the right middle lobe of the lung on the morning of Day 2.
Other Names:
7 mCi of [18F](+/-)NOS will be injected intravenously at the start of a 60-minute dynamic PET scan acquisition
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Distribution volume ratio (DVR), determined by Logan plot analysis, in the right middle lobe
Time Frame: Change in DVR on post-endotoxin PET scan (Day 2) from baseline (Day 1)
|
Comparison of DVR by Logan plot for [18F](+/-)NOS uptake, pulmonary blood flow (PBF) and extravascular lung water (EVLW) in the regions of interest generated from scans obtained before and after endotoxin instillation and in the right and left lungs will be compared using a repeated-measures t-test, with statistical significance set at p<0.05.
The DVR determined for [18F](+/-)NOS normalized for either PBF or EVLW will also be compared using a repeated-measures t-test before and after endotoxin as well as in the right and left lungs to determine whether differences in [18F](+/-)NOS uptake depend on either PBF or EVLW.
|
Change in DVR on post-endotoxin PET scan (Day 2) from baseline (Day 1)
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Change in DVR in right middle lobe
Time Frame: post-endotoxin scan (Day 2) from baseline (Day 1) scan
|
post-endotoxin scan (Day 2) from baseline (Day 1) scan
|
|
Mean Hounsfield units (HU), measure of density on CT images, in right middle lobe and lingula
Time Frame: baseline PET/CT scan on Day 1 to post-endotoxin scan on Day 2
|
baseline PET/CT scan on Day 1 to post-endotoxin scan on Day 2
|
|
Change in HU in right middle lobe and lingula
Time Frame: before and after endotoxin instillation (Day 1 to Day 2)
|
before and after endotoxin instillation (Day 1 to Day 2)
|
|
Bronchoalveolar lavage (BAL) cell counts (including total nucleated and neutrophil counts)
Time Frame: 6 hours post-endotoxin instillation
|
6 hours post-endotoxin instillation
|
|
Number and percent of iNOS-stained BAL cells by flow cytometry
Time Frame: 6 hours post-endotoxin instillation
|
6 hours post-endotoxin instillation
|
|
Number and percent of 3-nitrotyrosine-stained cells on biopsy
Time Frame: 6 hours post-endotoxin instillation
|
6 hours post-endotoxin instillation
|
|
Change in exhaled nitric oxide (ENO) levels
Time Frame: before and after endotoxin instillation (Day 1 to Day 2)
|
before and after endotoxin instillation (Day 1 to Day 2)
|
|
Regional PBF and EVLW in right middle lobe and lingula
Time Frame: before and after endotoxin (Day 1 to Day 2)
|
before and after endotoxin (Day 1 to Day 2)
|
|
Number of iNOS positive cells from brushing cytospins
Time Frame: 6 hours post-endotoxin instillation
|
6 hours post-endotoxin instillation
|
Collaborators and Investigators
Collaborators
Investigators
- Principal Investigator: Delphine Chen, MD, Washington University School of Medicine
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- DDCF 2010060-201403017
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Lung Inflammation
-
Medical University of ViennaCompletedExperimental Lung InflammationAustria
-
Environmental Protection Agency (EPA)Enrolling by invitationLung Inflammation | Experimental Lung InflammationUnited States
-
National Institutes of Health Clinical Center (CC)Enrolling by invitationAcute Lung InflammationUnited States
-
University of California, Los AngelesCompletedAsthma | Distal Lung InflammationUnited States
-
Washington University School of MedicineNational Heart, Lung, and Blood Institute (NHLBI); National Institutes of Health...Recruiting
-
Duke UniversityUniversity of Pennsylvania; National Heart, Lung, and Blood Institute (NHLBI)RecruitingLung Transplant Rejection | Lung Transplant Failure | Lung Transplant; Complications | Lung Transplant; Infection or InflammationUnited States, Canada
-
National Institute of Environmental Health Sciences...CompletedLung Inflammation | PolymorphismUnited States
-
Oslo University HospitalNorwegian Defence Research EstablishmentCompletedMarkers of Inflammation | Lung Function TestsNorway
-
Karolinska InstitutetSwedish Heart Lung FoundationCompleted
-
Washington University School of MedicineDoris Duke Charitable FoundationCompletedLung InflammationUnited States
Clinical Trials on Endotoxin (E. coli O:113, Reference Endotoxin)
-
Radboud University Medical CenterCompletedSepsis | Endotoxemia | Systemic Inflammation | ImmunosuppresionNetherlands
-
National Jewish HealthNot yet recruitingAsthma | Asthma; EosinophilicUnited States
-
Washington University School of MedicineBarnes-Jewish HospitalCompleted
-
Ohio State UniversityNational Institute of Mental Health (NIMH)Recruiting
-
Herlev HospitalUnknown
-
University of AarhusCompletedMetabolic Diseases | Inflammation | Febrile Illness AcuteDenmark
-
Penn State UniversityUnited States Department of Agriculture (USDA)Completed
-
University of Alabama at BirminghamAmerican Fibromyalgia Syndrome AssociationCompleted
-
Medical University of ViennaCompletedHealthy Subjects | Imparied Retinal Vascular ReactivityAustria